Drug Trial Radar · NCT05316922
TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients
Last checked: Nov 20, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Dec 13, 2021
Primary completion
Sep 30, 2029
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To offer the possibility of a treatment that could achieve a meaningful reduction in the incidence of post-radiation therapy hypothyroidism. Thyroid dysfunction may develop from a few months to several years after patients have completed their radiation treatment. In children with chronic diseases, or given lengthy anti-neoplastic treatments, recurrent or persistent endocrine disorders may have a negative effect on growth and development into adulthood.
Conditions
- Hypothyroidism; Irradiation
Interventions
LevothyroxineDrug
Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hypothyroidism-free survivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.